myVax™ - Intelligent, Patient-centered Health Platform

CDC NEWS

Latest News

An Updated Covid Guide For four different types of households.

17 May 2021

The new C.D.C. guidance has excited many Americans and scared many others. Some people feel both emotions, understandably enough: They’re excited to start returning to more normal daily life and still scared by a pandemic that is killing about 600 Americans a day. This morning, I want to think through the real-world implications of the new guidelines for individual families. Those guidelines mostly allow people to behave more freely. But they will also lead some to take new precautions. I am going to break down households into four categories, depending on vaccination status:

Breakthrough Infections Rare Among Vaccinated Americans

19 Apr 2021

In the United States, the Centers for Disease Control and Prevention provided its first public data about breakthrough Covid-19 cases to CNN last week and it shows that vaccines have been highly effective at reducing infections, hospitalizations and death. As of last week, around 78.5 million Americans had been fully vaccinated and the CDC's data states that 5,800 cases of Covid-19 occurred among fully vaccinated people, 396 of whom required hospitalization with 74 deaths recorded.

U.S. Calls for Pause on Johnson & Johnson Vaccine After Clotting Cases

13 Apr 2021

The Food and Drug Administration and the Centers for Disease Control will stop using the vaccine at federal sites and urge states to do so as well while they examine the safety issues.

Likely Legal, ‘Vaccine Passports’ Emerge as the Next Coronavirus Divide

07 Apr 2021

Businesses and universities want fast, easy ways to see if students and customers are vaccinated, but conservative politicians have turned “vaccine passports” into a cultural flash point.

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis

23 Mar 2021

79% vaccine efficacy at preventing symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalization Comparable efficacy result across ethnicity and age, with 80% efficacy in participants aged 65 years and over Favorable reactogenicity and overall safety profile

SARS-CoV-2 Vaccines

26 Feb 2021

Shortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein (particularly in its prefusion [native] conformation) was identified as the immunodominant antigen of the virus. Evaluation of patients with SARS-CoV-2 revealed that binding and neutralizing antibodies primarily target the receptor-binding domain of the S1 subunit.

SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities

17 Feb 2021

. SARS-CoV-2, like other RNA viruses, constantly changes through mutation, with new variants occurring over time. Generally, when new variants become more common, they do so because of some selective advantage to the virus.

The US Regulatory System and COVID-19 Vaccines The Importance of a Strong and Capable FDA

15 Feb 2021

For many in public health and medicine, the coronavirus disease 2019 (COVID-19) pandemic in the US has been a frustrating journey from one disappointment to the next: late access to testing, insufficient staff and inadequate funding for contact tracing, jumbled communications, and, at the end of 2020, a chaotic launch of vaccination efforts.

COVID-19 Vaccination in Pregnant and Lactating Women

08 Feb 2021

Pregnant women with severe or critical coronavirus disease 2019 (COVID-19) infection are at increased risk for preterm birth and pregnancy loss.

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

04 Feb 2021

We recently reported the results of a phase 1 trial of a messenger RNA vaccine, mRNA-1273, to prevent infection with SARS-CoV-2; those interim results covered a period of 57 days after the first vaccination.